Add up the top-line R&D spending for the top 10 pharma companies in the world and you'd think that nothing had changed from 2011 to 2012. But you'd be very wrong. Big Pharma's heavy hitters in R&D have a wildly mixed record in a fast-changing field. It will be an interesting year ahead. Here's a look at last year's results, and an analysis of where they point. Read the report >>
The FDA has opened the inside track to Novartis' experimental lung cancer drug, which gained "Breakthrough Therapy" designation that speeds the development and review schedules for new treatments. The Swiss drug giant ($NVS) plans to file for approval the drug, now in mid-stage clinical trials, in early 2014.
Novartis has added two more mobile apps to its constellation of digital offerings. This time, cancer patients are the target audience.
Here we present the Top 5 vaccine companies based on their 2012 vaccine revenues, filtered out of company reports by EvaluatePharma. Take a look and let us know what you think. We always like to hear how you view and evaluate the data.
Drugmakers in Europe are panicking over the possibility that come July, they are not going to have the APIs they need to make their products. And so they keep pleading with the European commission to cut them some slack.
Novartis Oncology has unleashed a pair of mobile phone apps that cater to patients or doctors, building on the pharma giant's digital outreach efforts that already include multiple offers on app stores from Google and Apple.
After closing out a failed Novartis partnership in January, Cytos Biotechnology has registered some upbeat data from a mid-stage study of its lead drug against allergic asthma. On the news, Zurich-based Cytos' shares jumped 14% as of early this morning, Bloomberg reported.
The court of public opinion passed quick judgment on Novartis and its 72-million-franc payout for departing chairman Daniel Vasella. The Swiss quickly said no, non and nein to that idea, and the company quickly abandoned that non-compete deal. But will an actual court have its chance to rule?
Swiss media report that Vasella is decamping from his home in Zug for greener pastures in the U.S.
Eisai's Fycompa is a first-of-its-kind seizure drug, a glutamate receptor antagonist and a blockbuster hopeful. The FDA gave the epilepsy drug its approval last year and the Japanese drugmaker is seeking approvals around the world. But Eisai has run into the German pricing agency buzzsaw, and, like its peers, says it is outraged at its treatment.